Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Hepion Pharmaceuticals, Inc. | a16-17622_1ex32d2.htm |
| EX-32.1 - EX-32.1 - Hepion Pharmaceuticals, Inc. | a16-17622_1ex32d1.htm |
| EX-31.2 - EX-31.2 - Hepion Pharmaceuticals, Inc. | a16-17622_1ex31d2.htm |
| EX-31.1 - EX-31.1 - Hepion Pharmaceuticals, Inc. | a16-17622_1ex31d1.htm |
| EX-21.1 - EX-21.1 - Hepion Pharmaceuticals, Inc. | a16-17622_1ex21d1.htm |
| 10-K - 10-K - Hepion Pharmaceuticals, Inc. | a16-17622_110k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
ContraVir Pharmaceuticals, Inc.
399 Thornall Street, First Floor
Edison, New Jersey 08837
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 No. 333-202625 and Form S-8 No. 333-203867 of ContraVir Pharmaceuticals, Inc. of our report dated September 28, 2016, relating to the consolidated financial statements, which appears in this Form 10-K for the year ended June 30, 2016. Our report on the consolidated financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
|
/s/ BDO USA, LLP |
|
|
Woodbridge, New Jersey |
|
|
|
|
|
September 28, 2016 |
|